A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases-Reference-Cited by-同舟云学术

A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases

Published:2021-12 Issue:6 Volume:19 Page:491-500
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Matsubara Nobuaki,Uemura Hirotsugu,Nagamori Satoshi,Suzuki Hiroyoshi,Uemura Hiroji,Kimura Go^ORCID

Funder

Taiho Pharmaceutical Co Ltd

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference23 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

3. Metastatic bone disease: clinical features, pathophysiology and treatment strategies;Coleman;Cancer Treat Rev,2001

4. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition)

5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate cancer version 4. 2019 National Comprehensive Cancer Network®. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Updated August 19, 2019. Accessed: January 17, 2020.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma;Frontiers in Oncology;2023-06-12

2. Osteomalacia in Adults: A Practical Insight for Clinicians;Journal of Clinical Medicine;2023-04-05